查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1848548

病毒载体生产市场（按载体类型、工作流程、给药方式、技术、适应症、应用和最终用户划分）－2025-2032年全球预测

Viral Vector Manufacturing Market by Vector Type, Workflow, Delivery Method, Technology, Disease Indication, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，病毒载体生产市场规模将达到 410 亿美元，复合年增长率为 20.54%。

主要市场统计数据
基准年 2024 91.9亿美元
预计年份：2025年 110亿美元
预测年份：2032年 410亿美元
复合年增长率 (%) 20.54%

本书简明扼要、权威地介绍了塑造现代病毒载体生产的科学进展、监管预期和运作实际情况。

病毒载体生产正处于一个关键的十字路口，科学创新、商业性动能和操作规范在此交汇融合。载体设计、细胞培养系统和纯化方法的最新进展拓展了治疗的可能性，同时也为生产带来了新的复杂性。研发人员和生产商如今面临着不断变化的监管要求、日益严格的品管以及生技药品在整个生产週期内保持效力和安全性。

随着相关人员积极应对这些压力，对自动化、一次性生物製程和分析平台的投资正在再形成工厂布局和技能要求。本应用文件结合科学驱动因素和实际生产情况，阐述了当前的行业格局，并强调成功取决于将工艺稳健性与对监管环境的前瞻性相结合。文件也着重指出，研发、製程开发、品质和供应链团队之间需要进行跨职能合作，才能将实验室的成果转化为可靠的临床和商业供应。

了解这些动态对于必须在临床试验时间和永续生产策略之间取得平衡的高阶主管和企业领导者至关重要。以下章节将深入剖析变革性变化、政策影响、细分市场洞察以及区域性考量，以展现现代病毒载体生产的策略整体情况。

深入探讨正在重新定义病毒载体生产产能、品质系统和劳动力需求的科技、监管和商业性变革

在科技、监管和商业性力量的共同推动下，病毒载体生产格局正在经历变革。在技​​术方面，转染和纯化技术的创新提高了产量、杂质控制和产品一致性的标准。这促使企业重新评估其平台选择，并采用混合製程架构，将生物反应器的可扩展性与新兴的一次性及连续下游解决方案相结合。随着工艺的演进，品质体係也不断发展。先进的线上製反应器分析和即时放行检测正成为验证控制和加速产品开发的关键。

不断变化的监管环境也是一个重要因素，监管机构强调基于风险的方法、生命週期监控和供应链透明度。因此，开发人员优先考虑那些能够促进可比性、变更管理以及核准后流程弹性的设计方案。随着基因治疗、肿瘤研究和疫苗学等临床计画的激增，需求模式也日益多样化，这就要求製造能力能够灵活适应，既能支持小规模、高复杂度的生产，又能支持大规模的宣传活动。

在营运层面，员工组成和能力模式正在发生变化，纳入更多製程分析、法规科学家和生技药品工程专家；同时，战略伙伴关係、合约开发和生产关係以及模组化设施正成为降低产能投资风险的首选机制。总而言之，这些转变显示该产业正从一次性、实验室规模的生产向工业化、品质主导生产转型，从而支持各种规模的多种治疗方法。

本文全面分析了近期美国关税措施如何重塑筹资策略、供应商韧性和在地化生产选择。

2025年，美国关税的实施增加了病毒载体生产生态系统的成本，并加剧了供应链的复杂性。这些关税影响了关键原料、一次性耗材和专用设备的筹资策略，促使各企业重新评估其供应商布局并探索替代采购管道。因此，製造商越来越重视供应商冗余、关键零件的近岸外包以及策略性库存管理，以维持生产的连续性。

累积效应促使企业重组供应商关係，并将焦点从单位成本转移到总落地成本。如今，企业更加重视供应商绩效指标、前置作业时间可靠性以及应对贸易措施对其营运影响的弹性计划。此外，关税也加速了关于在地化生产的讨论，促使企业权衡在区域工厂的资本投资与第三方製造伙伴关係关係所提供的灵活性之间的利弊。

重要的是，这种政策环境刺激了采购和物流的创新，包括集中运输、保税仓库和联合采购联盟。这些调整使一些製造商能够在保持合规性和品质标准的同时，部分抵消不断上涨的进口成本。展望未来，企业领导者正将关税情境规划纳入其资本和供应链策略，以保持灵活性并保障临床和商业供应的连续性。

详细的细分情报揭示了载体生物学、工作流程架构、递送方式、赋能技术、治疗适应症、应用和最终用户概况如何决定生产策略。

细分市场分析揭示了载体生物学、工作流程阶段、递送方式、赋能技术、治疗重点、应用和最终用户画像等方面的细微驱动因素和营运重点差异。依载体类型划分，本文检视了腺病毒载体、桿状病毒载体、单纯疱疹病毒载体、慢病毒载体、质体DNA和逆转录病毒，每种载体都具有不同的嗜性、有效载荷能力和下游纯度挑战，这些挑战会影响製程设计和分析需求。基于工作流程，市场分为下游製程和上游工艺，下游製程进一步细分为製剂和纯化，上游製程进一步细分为反应器、细胞培养系统和培养基配方。这种细分突出表明，上游製程（例如细胞培养系统）的选择会直接影响下游纯化负担和製剂稳定性要求。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 利用一次性反应器系统扩大腺结合病毒的生产规模，以满足商业需求。
  • 整合连续生产和随线分析，以优化病毒载体生产效率
  • 采用高通量数位监控和人工智慧驱动的製程控制，以确保载体品质的一致性。
  • 利用层析法纯化技术提高病毒载体的效力和产量
  • 基因疗法开发商与合约研发生产机构之间的策略伙伴关係消除了生产瓶颈
  • 引入无血清培养基配方以降低病毒载体培养中的污染风险
  • 监管协调工作旨在简化全球病毒载体生产设施的核准
  • 一种去中心化的照护现场载体生产模式，用于支持个人化基因治疗
  • 开发稳定的生产细胞株，以最大限度地减少短暂转染的变异性和成本。
  • 无菌灌装和包装技术的创新将加速病毒载体产品的上市速度

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按载体类型分類的病毒载体生产市场

  • 腺病毒载体
  • 桿状病毒载体
  • 单纯疱疹病毒载体
  • 慢病毒载体
  • 质体DNA
  • 逆转录病毒

9. 按工作流程分類的病毒载体生产市场

  • 下游加工
    • 组合
    • 纯化
  • 上游加工
    • 反应器
    • 细胞培养系统
    • 中等配方

10. 按递送方式分類的病毒载体生产市场

  • 体外
    • 细胞再注射
    • 细胞转导
  • 体内
    • 缸内直喷
    • 静脉注射
    • 口服

第十一章 病毒载体生产市场（依技术划分）

  • 净化技术
    • 层析法
    • 超过滤
  • 转染方法
    • 化学
    • 电穿孔

第十二章 依适应症分類的病毒载体生产市场

  • 心血管疾病
  • 遗传性疾病
  • 感染疾病
  • 代谢紊乱

第十三章 病毒载体生产市场（依应用领域划分）

  • 基因治疗
    • 遗传性疾病
    • 肿瘤性疾病
    • 单基因突变
  • 肿瘤学研究
    • 基因惰性
    • 溶瘤病毒疗法
    • 肿瘤抑制基因
  • 疫苗
    • 癌症疫苗
    • 感染疾病
    • 通用感染疾病

第十四章 病毒载体生产市场（依最终用户划分）

  • 生技公司
    • 大公司
    • Start-Ups
  • 製药公司
    • 製造业
    • 研究与开发
  • 研究所
    • 学术实验室
    • 政府实验室

第十五章 病毒载体生产市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 病毒载体生产市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 各国病毒载体生产市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • ABL Inc.
    • Batavia Biosciences BV by CJ Cheiljedang
    • Biovian Oy
    • Charles River Laboratories International, Inc.
    • Creative Biogene
    • Danaher Corporation
    • FinVector Oy
    • FUJIFILM Diosynth BIoTechnologies USA, Inc.
    • GE HealthCare Technologies, Inc.
    • Genezen Laboratories, Inc.
    • Kaneka Eurogentec SA
    • Lonza Group Ltd.
    • MaxCyte, Inc.
    • Merck KGaA
    • Miltenyi BIoTec GmbH
    • Novartis AG
    • Oxford Biomedica PLC
    • Sanofi SA
    • Sirion-BIoTech GmbH
    • Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
    • Takara Bio Inc.
    • Thermo Fisher Scientific Inc.
    • uniQure NV
    • VGXI, Inc. by GeneOne Life Science
    • Waisman Biomanufacturing
    • Wuxi AppTec Co., Ltd.
Product Code: MRR-FD3F12D54086

The Viral Vector Manufacturing Market is projected to grow by USD 41.00 billion at a CAGR of 20.54% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.19 billion
Estimated Year [2025] USD 11.00 billion
Forecast Year [2032] USD 41.00 billion
CAGR (%) 20.54%

A concise, authoritative introduction connecting scientific advances, regulatory expectations, and operational realities shaping contemporary viral vector manufacturing

Viral vector manufacturing stands at a pivotal juncture where scientific innovation, commercial momentum, and operational rigor intersect. Recent advances in vector design, cell culture systems, and purification methodologies have expanded therapeutic possibilities while simultaneously introducing new layers of manufacturing complexity. Developers and manufacturers now confront evolving regulatory expectations, heightened quality controls, and the technical demands of scaling biologics that must preserve potency and safety across production runs.

As stakeholders respond to these pressures, investments in automation, single-use bioprocessing, and analytic platforms are reshaping factory footprints and skill requirements. This introduction contextualizes the current landscape by connecting scientific drivers to practical manufacturing realities, emphasizing that success depends on integrating process robustness with regulatory foresight. It further highlights the need for cross-functional collaboration among research, process development, quality, and supply chain teams to translate laboratory promise into reliable clinical and commercial supply.

Understanding these dynamics is essential for senior executives and operational leaders who must balance time-to-clinic imperatives with sustainable manufacturing strategies. The following sections unpack transformative shifts, policy impacts, segmentation-specific insights, and regionally differentiated considerations that together form a strategic picture of contemporary viral vector manufacturing.

An in-depth exploration of the technological, regulatory, and commercial transformations redefining capacity, quality systems, and workforce needs across viral vector manufacturing

The viral vector manufacturing landscape is undergoing transformative shifts driven by converging technological, regulatory, and commercial forces. On the technological front, innovations in transfection methods and purification techniques are raising the bar for yield, impurity control, and product consistency. This has led organizations to reassess platform choices and to adopt hybrid process architectures that marry the scalability of bioreactors with emerging single-use and continuous downstream solutions. As processes evolve, so too do quality systems; advanced in-process analytics and real-time release testing are becoming central to demonstrating control and enabling accelerated development pathways.

Regulatory evolution is another major factor, with authorities emphasizing risk-based approaches, lifecycle oversight, and supply chain transparency. Consequently, developers are prioritizing design spaces that facilitate comparability, change control, and post-approval process flexibility. Commercial dynamics also contribute to change: as clinical programs proliferate across gene therapy, oncology research, and vaccinology, demand profiles have become more heterogeneous, requiring adaptable manufacturing capacities that can support smaller, high-complexity runs alongside larger-scale campaigns.

Operationally, workforce composition and competency models are shifting to include a larger share of process analytics, regulatory scientists, and specialists in biologics engineering. Meanwhile, strategic partnerships, contract development and manufacturing relationships, and modular facilities are emerging as preferred mechanisms to de-risk capacity investments. Taken together, these shifts indicate a sector moving from one-off, lab-scale production toward industrialized, quality-driven manufacturing that supports diverse therapeutic modalities at varying scales.

A comprehensive analysis of how recent United States tariff measures have reshaped procurement strategies, supplier resilience, and regional manufacturing localization choices

In 2025, tariff policies in the United States introduced additional costs and supply chain complexities that reverberated across viral vector manufacturing ecosystems. These tariffs have impacted the sourcing strategies for critical raw materials, single-use disposables, and specialized equipment, prompting organizations to reassess supplier footprints and to explore alternative procurement pathways. As a result, manufacturers have increasingly emphasized supplier qualification redundancy, nearshoring of key components, and strategic inventory management to preserve production continuity.

The cumulative effect has been a reshaping of supplier relationships and a renewed focus on total landed cost rather than unit price alone. Companies now place greater emphasis on supplier performance metrics, lead-time reliability, and resilience planning to mitigate the operational impacts of trade measures. In addition, the tariffs have accelerated discussions around manufacturing localization as organizations weigh the trade-offs between capital investment in regional facilities and the flexibility afforded by third-party manufacturing partnerships.

Importantly, the policy environment has stimulated innovation in procurement and logistics, such as consolidated shipping, bonded warehousing, and aggregated purchasing consortia. These adaptations are enabling some manufacturers to partially offset increased import costs while maintaining regulatory compliance and quality standards. Looking ahead, leaders are integrating tariff scenario planning into capital and supply chain strategies to maintain agility and protect continuity of clinical and commercial supply.

In-depth segmentation intelligence revealing how vector biology, workflow architecture, delivery modalities, enabling technologies, therapeutic indications, applications, and end-user profiles dictate manufacturing strategy

Segmentation analysis reveals nuanced drivers and operational priorities that vary by vector biology, workflow stage, delivery modality, enabling technology, therapeutic focus, application, and end user profile. Based on Vector Type, the market is studied across Adenoviral Vectors, Baculoviral Vectors, Herpes Simplex Vectors, Lentiviral Vectors, Plasmid DNA, and Retrovirus, each presenting distinct tropism, payload capacity, and downstream purity challenges that influence process design and analytics needs. Based on Workflow, the market is studied across Downstream Processing and Upstream Processing, where Downstream Processing is further studied across Formulation and Purification and Upstream Processing is further studied across Bioreactors, Cell Culture Systems, and Media Formulations; this division underscores how upstream choices such as cell culture systems directly affect downstream purification loads and formulation stability requirements.

Based on Delivery Method, the market is studied across Ex Vivo and In Vivo, with the Ex Vivo further studied across Cell Re-infusion and Cell Transduction and the In Vivo further studied across Direct Injection, Intravenous Route, and Oral Administration; these delivery distinctions drive product specifications, sterility controls, and cold chain demands, influencing manufacturing batch sizes and release strategies. Based on Technology, the market is studied across Purification Techniques and Transfection Methods, where the Purification Techniques category is further studied across Chromatography and Ultrafiltration and the Transfection Methods category is further studied across Chemical-Based and Electroporation approaches; technology choices determine process footprint, consumables consumption, and validation complexity.

Based on Disease Indication, the market is studied across Cardiovascular Diseases, Genetic Disorders, Infectious Diseases, and Metabolic Disorders, each with different patient populations, route-of-administration preferences, and regulatory considerations that shape development timelines. Based on Application, the market is studied across Gene Therapy, Oncology Research, and Vaccinology, where Gene Therapy is further studied across Inherited Disorders, Oncological Disorders, and Single Gene Mutations, Oncology Research is further studied across Gene Inactivation, Oncolytic Virotherapy, and Tumor Suppressor Genes, and Vaccinology is further studied across Cancer Vaccines, Infectious Diseases, and Zoonotic Diseases; these application-level distinctions inform the acceptable risk-benefit profile and, consequently, the manufacturing rigor and batch release criteria. Based on End User, the market is studied across Biotechnology Companies, Pharmaceutical Companies, and Research Institutions, where Biotechnology Companies is further studied across Large Enterprises and Start-Ups, Pharmaceutical Companies is further studied across Manufacturing and Research and Development, and Research Institutions is further studied across Academic Laboratories and Government Labs; each end-user segment exhibits different tolerances for capital intensity, preferred partnership models, and expectations for technical support and regulatory guidance.

Synthesizing these segmentation insights highlights that manufacturing strategies cannot be one-size-fits-all. Vector biology informs process constraints, workflow segmentation pinpoints critical handoffs that impact yield and quality, delivery method determines stability and dose strategy, technology selection dictates capital and operational expenditure profiles, disease indication frames regulatory and clinical risks, application context sets the commercial cadence, and end-user archetypes drive partnership structures and investment horizons. Consequently, organizations planning capacity expansion, technology adoption, or market entry must align choices across these segmentation dimensions to optimize product integrity, time-to-clinic, and downstream scalability.

Strategic regional perspectives on manufacturing capacity, regulatory complexity, and supply chain resilience across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets

Regional dynamics continue to exert a decisive influence on manufacturing strategy, regulatory interactions, and commercial deployment. In the Americas, robust venture funding, advanced clinical pipelines, and established contract manufacturing infrastructures support rapid program advancement, yet cost pressures and trade policy considerations require careful supply chain design. In Europe, Middle East & Africa, regulatory harmonization efforts coexist with diverse national requirements, prompting manufacturers to build flexible quality systems and leverage regional CMO networks to navigate heterogeneous approval pathways. In the Asia-Pacific region, investments in bioprocessing capabilities and a growing base of domestic suppliers have expanded local manufacturing options, accelerating localized production for regional clinical studies and commercial supply.

Across these regions, talent availability, infrastructure maturity, and policy frameworks vary significantly, which affects timelines for facility qualification, material sourcing, and cross-border regulatory submissions. Consequently, strategic planners must account for regional nuances when selecting manufacturing partners, locating capacity, and designing distribution channels. For global programs, a hybrid approach that combines regional manufacturing nodes with centralized analytic and quality oversight often yields the best balance of responsiveness, cost control, and compliance.

A strategic assessment of the competitive landscape showing how process expertise, integrated platform providers, and collaborative partnerships are reshaping capability and capacity competition

Key companies in the viral vector manufacturing ecosystem are shaping the industry through differentiated capabilities in process development, scale-up, analytical services, and manufacturing capacity. Established contract manufacturers continue to expand capacity and technical offerings, integrating advanced purification platforms and modular cleanroom solutions to meet varied client needs. Biotech innovators are simultaneously pushing the envelope in vector design and transfection chemistries, which has created demand for specialized process development partnerships and bespoke analytical methods.

In addition, technology providers supplying bioreactors, single-use systems, chromatography resins, and ultrafiltration modules play a pivotal role in defining operational efficiency and cost structure. Companies offering end-to-end solutions that couple upstream optimization with downstream robustness and formulation expertise are gaining traction among organizations pursuing accelerated development timelines. Moreover, cross-sector collaborations between pharmaceutical firms, academic centers, and government laboratories are becoming more frequent, enabling shared access to specialized equipment, rare expertise, and manufacturing capacity during critical program stages.

Taken together, the competitive landscape favors organizations that can demonstrate technical depth, flexible capacity models, and proven quality systems; companies that invest in interoperability of platforms, digital process control, and robust supplier ecosystems will be best positioned to capture emerging opportunities across therapeutic areas.

Actionable operational and strategic recommendations for leaders to strengthen resilience, quality systems, regional capacity choices, and technology investments for viral vector manufacturing

To convert insight into operational advantage, industry leaders should prioritize a set of targeted actions focused on resilience, quality, and strategic investment. First, align platform selection with anticipated clinical and commercial profiles, ensuring that vector type and delivery method choices are supported by validated upstream and downstream train designs. Second, invest in supplier qualification and dual-sourcing strategies for critical consumables and equipment to mitigate the impacts of trade measures and logistical disruptions. Third, accelerate adoption of process analytical technology and digital control systems to reduce cycle variability and enable data-driven release strategies.

In parallel, leaders should evaluate the merits of regional capacity diversification by balancing near-term agility with longer-term cost considerations, and pursue flexible partnership models such as toll manufacturing and capacity reservation agreements. Workforce development is equally critical: build multidisciplinary teams that bring together process scientists, regulatory experts, and supply chain strategists to ensure that decisions are robust across the product lifecycle. Finally, integrate scenario-based planning for regulatory changes and tariff fluctuations into capital and operational planning cycles to preserve optionality and reduce risk to patient supply.

By executing these recommendations, organizations can strengthen their operational resilience, shorten development timelines, and improve the predictability of manufacturing outcomes while safeguarding product quality and regulatory compliance.

A transparent, multi-method research approach integrating primary interviews, technical literature review, and cross-case analysis to produce actionable manufacturing insights

This research synthesis draws on a multi-method approach combining primary interviews, technical literature review, and comparative analysis of regulatory guidance and industry practice. Primary inquiry involved structured conversations with process development scientists, manufacturing leaders, quality assurance professionals, and procurement executives to surface practical constraints, adoption drivers, and operational priorities. Secondary sources included peer-reviewed journals, technical white papers, and public regulatory documents to ensure that technological and compliance assertions reflect current standards and scientific consensus.

Qualitative synthesis was complemented by cross-case analysis of manufacturing approaches to identify commonalities in platform selection, workflow handoffs, and risk mitigation strategies. Special attention was given to triangulating claims about technology performance with independent technical reports and vendor specifications to avoid undue reliance on promotional materials. Throughout the analysis, confidentiality was maintained for proprietary data shared by participants, and interpretations were calibrated to emphasize generalizable insights rather than firm-specific claims.

A concise, forward-looking conclusion summarizing strategic imperatives for operationalizing robust, scalable, and compliant viral vector manufacturing

In summary, viral vector manufacturing is transitioning from artisanal, program-specific production toward more industrialized, quality-centric operations that support diverse therapeutic modalities. This transition is being shaped by advances in purification and transfection technologies, evolving regulatory expectations, and commercial dynamics that demand agility across development and supply. Tariff-induced procurement shifts have highlighted the importance of resilient supplier networks and regional manufacturing strategies, while segmentation analysis underscores that optimal process designs must be tailored to vector type, workflow architecture, delivery method, technology choice, disease indication, application, and end-user needs.

For decision-makers, the imperative is clear: invest in flexible, data-driven manufacturing platforms, foster strategic supplier relationships, and build cross-functional capabilities to bridge research and large-scale production. By doing so, organizations can reduce technical and regulatory risk, improve time-to-clinic, and create a foundation for sustainable commercial supply of vector-based therapies. The path forward requires disciplined execution, informed technology choices, and a strategic balance between in-house capabilities and external partnerships.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Scaling up adeno-associated virus production using single-use bioreactor systems for commercial demands
  • 5.2. Integration of continuous manufacturing and inline analytics to optimize viral vector process efficiency
  • 5.3. Adoption of high-throughput digital monitoring and AI-driven process control for vector quality consistency
  • 5.4. Advancements in chromatography-based purification to improve viral vector potency and yield
  • 5.5. Strategic partnerships between gene therapy developers and CDMOs to address manufacturing bottlenecks
  • 5.6. Implementation of serum-free media formulations to reduce contamination risks in viral vector cultures
  • 5.7. Regulatory harmonization efforts to streamline global approvals for viral vector manufacturing facilities
  • 5.8. Decentralized point-of-care vector manufacturing models to support personalized gene therapies
  • 5.9. Development of stable producer cell lines to minimize transient transfection variability and costs
  • 5.10. Innovations in aseptic fill-and-finish technologies to accelerate time-to-market for viral vector products

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Viral Vector Manufacturing Market, by Vector Type

  • 8.1. Adenoviral Vectors
  • 8.2. Baculoviral Vectors
  • 8.3. Herpes Simplex Vectors
  • 8.4. Lentiviral Vectors
  • 8.5. Plasmid DNA
  • 8.6. Retrovirus

9. Viral Vector Manufacturing Market, by Workflow

  • 9.1. Downstream Processing
    • 9.1.1. Formulation
    • 9.1.2. Purification
  • 9.2. Upstream Processing
    • 9.2.1. Bioreactors
    • 9.2.2. Cell Culture Systems
    • 9.2.3. Media Formulations

10. Viral Vector Manufacturing Market, by Delivery Method

  • 10.1. Ex Vivo
    • 10.1.1. Cell Re-infusion
    • 10.1.2. Cell Transduction
  • 10.2. In Vivo
    • 10.2.1. Direct Injection
    • 10.2.2. Intravenous Route
    • 10.2.3. Oral Administration

11. Viral Vector Manufacturing Market, by Technology

  • 11.1. Purification Techniques
    • 11.1.1. Chromatography
    • 11.1.2. Ultrafiltration
  • 11.2. Transfection Methods
    • 11.2.1. Chemical-Based
    • 11.2.2. Electroporation

12. Viral Vector Manufacturing Market, by Disease Indication

  • 12.1. Cardiovascular Diseases
  • 12.2. Genetic Disorders
  • 12.3. Infectious Diseases
  • 12.4. Metabolic Disorders

13. Viral Vector Manufacturing Market, by Application

  • 13.1. Gene Therapy
    • 13.1.1. Inherited Disorders
    • 13.1.2. Oncological Disorders
    • 13.1.3. Single Gene Mutations
  • 13.2. Oncology Research
    • 13.2.1. Gene Inactivation
    • 13.2.2. Oncolytic Virotherapy
    • 13.2.3. Tumor Suppressor Genes
  • 13.3. Vaccinology
    • 13.3.1. Cancer Vaccines
    • 13.3.2. Infectious Diseases
    • 13.3.3. Zoonotic Diseases

14. Viral Vector Manufacturing Market, by End User

  • 14.1. Biotechnology Companies
    • 14.1.1. Large Enterprises
    • 14.1.2. Start-Ups
  • 14.2. Pharmaceutical Companies
    • 14.2.1. Manufacturing
    • 14.2.2. Research and Development
  • 14.3. Research Institutions
    • 14.3.1. Academic Laboratories
    • 14.3.2. Government Labs

15. Viral Vector Manufacturing Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Viral Vector Manufacturing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Viral Vector Manufacturing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. ABL Inc.
    • 18.3.2. Batavia Biosciences B.V. by CJ Cheiljedang
    • 18.3.3. Biovian Oy
    • 18.3.4. Charles River Laboratories International, Inc.
    • 18.3.5. Creative Biogene
    • 18.3.6. Danaher Corporation
    • 18.3.7. FinVector Oy
    • 18.3.8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
    • 18.3.9. GE HealthCare Technologies, Inc.
    • 18.3.10. Genezen Laboratories, Inc.
    • 18.3.11. Kaneka Eurogentec S.A.
    • 18.3.12. Lonza Group Ltd.
    • 18.3.13. MaxCyte, Inc.
    • 18.3.14. Merck KGaA
    • 18.3.15. Miltenyi Biotec GmbH
    • 18.3.16. Novartis AG
    • 18.3.17. Oxford Biomedica PLC
    • 18.3.18. Sanofi SA
    • 18.3.19. Sirion-Biotech GmbH
    • 18.3.20. Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
    • 18.3.21. Takara Bio Inc.
    • 18.3.22. Thermo Fisher Scientific Inc.
    • 18.3.23. uniQure N.V.
    • 18.3.24. VGXI, Inc. by GeneOne Life Science
    • 18.3.25. Waisman Biomanufacturing
    • 18.3.26. Wuxi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. VIRAL VECTOR MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. VIRAL VECTOR MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VIRAL VECTOR MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BACULOVIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BACULOVIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BACULOVIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BACULOVIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BACULOVIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BACULOVIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOREACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOREACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOREACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL CULTURE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL CULTURE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL CULTURE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL CULTURE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL CULTURE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL CULTURE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MEDIA FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MEDIA FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MEDIA FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MEDIA FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MEDIA FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MEDIA FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL RE-INFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL RE-INFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL RE-INFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL RE-INFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL RE-INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL RE-INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL TRANSDUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL TRANSDUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL TRANSDUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL TRANSDUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL TRANSDUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL TRANSDUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DIRECT INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DIRECT INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DIRECT INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DIRECT INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DIRECT INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DIRECT INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INTRAVENOUS ROUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INTRAVENOUS ROUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INTRAVENOUS ROUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INTRAVENOUS ROUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INTRAVENOUS ROUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INTRAVENOUS ROUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHEMICAL-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHEMICAL-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHEMICAL-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHEMICAL-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHEMICAL-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHEMICAL-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INHERITED DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INHERITED DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INHERITED DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INHERITED DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INHERITED DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INHERITED DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SINGLE GENE MUTATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SINGLE GENE MUTATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SINGLE GENE MUTATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SINGLE GENE MUTATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SINGLE GENE MUTATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SINGLE GENE MUTATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE INACTIVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE INACTIVATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE INACTIVATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE INACTIVATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE INACTIVATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE INACTIVATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TUMOR SUPPRESSOR GENES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TUMOR SUPPRESSOR GENES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TUMOR SUPPRESSOR GENES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TUMOR SUPPRESSOR GENES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TUMOR SUPPRESSOR GENES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TUMOR SUPPRESSOR GENES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ZOONOTIC DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ZOONOTIC DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ZOONOTIC DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ZOONOTIC DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ZOONOTIC DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ZOONOTIC DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)

TABLE